INTRODUCTION
Positron-emitting, labeled radiopharmaceuticals are used in conjunction with Positron Emission Tomography (PET) in various areas of clinical research. The positron-emitting radionuclide 18F (T112=109.7 min) has great potential in nuclear medicine as a label for radiopharmaceuticals.
[18F]-2-deoxy-2-fluoro-D-glucose (FDG), a glucose analog, is used in the investigation of myocardial and cerebral glucose metabolism as well as in brain tumors' ; the labeled analog of L-dopa, [18F]-6-Fluoro-L-Dopa (FDOPA), is a radiopharmaceutical that has potential use in the quantitative measurement of the kinetics of cerebral dopamine metabolism 2-3) and 18F-5-fluorodeoxyuridine (FdUR), a fluorinated pyrimidine, has been useful in tumor detection4 6) .
Knowledge of the internal radiation dose resulting from the use of nuclear medicines is a prerequisite for making radiation risk estimations to patients, often volunteers, in whom the first assessment of these radiopharmaceuticals is made. Values for absorbed doses resulting from the administration of FDG and FDOPA have been published 7-". For FDG, Jones et al.9 reported absorbed doses estimated from activity measurements for the brain and bladder in h1imans, doses to other organs being calculated from the biodistribution data for the dog of Gallagher et al. 11). Harvey et al. 1 °) calculated the absorbed doses in humans after the administration of FDOPA using the organ biodistribution data of this compound in dogs. No absorbed doses from the administration of FdUR have been reported.
In a previous study' 2) we reported the absorbed doses estimated from PET measure ments of time-activity curves in six human organs, besides the brain and bladder, after the administration of 18F-FDG. We report the absorbed doses estimated for FDOPA and FdUR, and compare them with those for FDG. Brain time-activity measurements made by PET in humans after the administration of FDOPA and the organ biodistribution data of this compound in mice were used for the absorbed dose calculations. Absorbed doses from the administration of FdUR were calculated from dog biodistribution data. 18F activity in the human bladder contents was monitored with a heavily collimated single detector. Absorbed dose calculations were made by the MIRD method modified for the Japanese physique in order to obtain a more realistic estimation. The effective dose equivalent also was estimated. The results were compared with those previously reported (9,10) on the radiation dosimetry of these compounds. The biokinetic data on source organs were obtained from clinical PET studies with 1sF FDG. Subjects were normal volunteers (total 18; age range: 23-60) from whom informed consent for measurements of organ metabolism with FDG had been obtained. Measure ments were made with the tomographs ECAT II built by ORTEC* and PT 931 by CTI**. Thirty-one sets of metabolic data for seven organs (brain, heart, kidney, liver, lung, pancreas and spleen) were available. Details of the methods used to obtain the biokinetic data, and absorbed dose calculations were reported elsewherel2>.
MATERIALS AND METHODS

Synthesis
There is a lack of biokinetic data in humans for FDOPA and FdUR because the former radiopharmaceutical is used specifically for brain studies and the latter for cancer detection. The absorbed dose estimation in human therefore has to be chiefly based on biodistribution studies done with animals. 2. Biodistribution of 18F-FDOPA in ddY mice.
The tissue distribution data for FDOPA in mice 16) was used for the dosimetric calcu lations. In this study, groups of 5 ddY mice were killed 1, 5, 10, 30, 60 and 120 min after injection, and ten body tissues excised. The activities in these tissues were measured with a NaI (T1) well-type scintillator. Only for the brain, time-activity curves were measured in humans by PET. Percentages of the injected activity present in the kidneys, liver and pancreas also were determined by PET measurements in a normal volunteer 1 h after injection.
Biodistribution of 18F-FdUR in dogs.
For FdUR, we made a biodistribution study in dogs. Two dogs (13.5 and 11.4 kg) were anesthetized with sodium pentobarbital, then each was injected with 37 MBq of FdUR. The dogs were killed 1 and 2 h after the respective injections, and dissected. Samples from each organ were weighed and the 18F activities measured with a well counter.
Biodistribution of 18F-FdUR in humans.
A rectilinear PET scan of a normal volunteer was taken 90 min after the injection of 18F -FdUR to determine the tissue radioactivity distribution in humans . The scan was done with a tomograph ECAT II in the low resolution mode. 5. Bladder time-activity measurements.
Excretion data for 18F activity in the bladder were measured in various subjects who were undergoing metabolic study with these radiopharmaceuticals. The 18F activity in the bladder contents was monitored with a heavily collimated CsI detector. The detector was placed 5 cm above the subject's bladder on a special support. Activity was recorded on a multi-channel analyzer in the MCS mode, during the clinical examination (1 to 2 h). The activity in the bladder was determined from the measurement of a urine sample, taken from the total voided volume, with a Nal (T1) well-counter. 6. Blood activity clearance.
Blood clearance studies were done in humans after intravenous administration of the three test compounds. Blood samples were taken from volunteers at different intervals after injection, up to approximately 1 h, and measured with the Nal (T1) well-counter .
Calculation of Cumulated Activity.
The calculation of the cumulated activity for FDG has been described elsewhere12), and is described here only for FDOPA and FdUR. 1. '8F-FDOPA.
The organ distribution of 18F-FDOPA activity in ddY mice, corrected for physical decay, was used to determine the retention function of the activity, R, in the source organs. Data were fitted by the least square methods to the function of two or three exponential terms as
where fhi is the intercept and ki the biological elimination rate constant. Values of fhi, expressed as percentages of the injected dose per organ, and of ki are shown in Table 2 .
Biological half-lives Tb CTb=lk ) and intercept parameters ahi, expressed as the fraction of the ith component at time t=0 per administered unit activity, were used in the following equation to obtain the residence time of the activity, Th, in the source organ, h, as
where Fi, is the distribution factor (the fractional distribution of the injected activity to organ or tissue h) that appears in Table 2 ; Thi, the effective half life: 
i where Qhi and Thi are the intercept and the effective half-life of the ith exponential component for total body, and FRB is the fraction of the injected activity retained in the rest of the body. The fraction retained, FRB, was 70% (100% minus the sum of the doses retained in the organs listed in Table 2 ). The retention function for the total body, excluding bladder content, RTB, was derived from the bladder activity excretion data for FDOPA in humans reported by Harvey et al. 10) . is expressed as (5) RTB(t) = 0.21e-u.257(min-1)-t + 0.79e-o.002(min_1).t
For the brain the cumulated activity was calculated from the time-activity curve which was fitted by the least squares method to the function of 5 exponential terms. The functions were integrated from zero to infinite time to give the cumulated activity as
where k is the physical decay constant. 2. 18F-FdUR.
For the calculations of the cumulated activity in the source organs, the organ uptake determined in dogs 60 min after intravenous injection of FdUR was used. It was assumed that the percentages of injected activity per organ at this time were present instantaneously after injection in human. An effective half-life equal to the physical half-life of the radionuclide (Teff=TPhy=109.8 min) also was assumed. The cumulated activity was calculated as
where Ah(O) is the initial uptake of activity in the organ. Cumulated activity for the rest of the body (RB) was calculated as the difference between the cumulated activity in total body (TB) and the sum of the individual cumulated activities in the source organs (hi) as ARB = ATB lAhi.
i 3. Cumulated activities in the bladder contents. The activity accumulated in the bladder contents after the administration of FDOPA was calculated from the kidney-bladder model developed by Cloutier et al., 7 . Based on the data for humans reported by Harvey et a1.10) we deduced that a fraction of 0.5 of the injected activity is eliminated by the renal system and that the cumulated activity can be calculated by the following equation, described in ICRP 53 statement 6718);
where fr is the fraction of excreted activity eliminated through the kidneys and t,, is the voiding interval (3.5 h). For FdUR, the data of Shani et al. of 18F labeled pyrimidine'9 on the cumulated activity in bladder in human was used (see Table 8 ). The cumulated activity of FDG was calculated 12) from the measured time-activity curves in the human bladder as A(µCi) 10 A = R(% -hr) H(%) , () where R is the area under the time-activity curve, H the height of the curve at void time, t, and A the total voided activity.
Absorbed Dose Calculations: Calculations were made by the MIRD method, in which the mean dose to the target organ is calculated as the product of the cumulated activity in the source organ, A, and the "S" values (absorbed dose per unit of cumulated activity)
, that is
h in which h, k and RB respectively represent the source organ, target organ and rest of the 
k where wk is the weighting factor of the organ and Hk is equal to the mean absorbed dose, Dk, because the quality factor, Q, for 18F is taken as unitary. 
RESULTS
Organ Biodistribution. 1. 18F-FDG: Figure 1 shows typical time-activity curves (corrected for physical decay) of FDG in brain, heart, kidney, liver, lung, pancreas and spleen. Activity is expressed as the percentage of injected activity per gram of tissue. Brain and heart have the highest uptakes of 18F activity in humans because this compound is trapped metabolically and tends to remain chiefly in organs with high hexokinase activity 27). The total activity for the organs was obtained by multiplying the percent of injected activity per gram of tissue by the organ mass of the Japanese Reference Man22>.
18F-FDOPA:
The organ distribution of FDOPA in ddY mice (corrected for physical decay) is shown in Table 1 and is expressed as the percent of injected dose per organ. The fitted parameters are given in Table 2 . Data for three organs were omitted because they were not considered source organs. High accumulations of 18F activity are present in the kidneys, liver and pancreas. Brain time-activity curves measured in humans are shown in Figure 2 . Respective percentages of injected activity determined by PET in a normal volunteer 1 h after injection to the kidney, liver and pancreas were 2.9, 4.8 and 1.1%, whereas values of 5.6, 0.7 and 0.9% were found for mice. 3. t8F-FdUR: Table 3 shows the biodistribution of FdUR in two dogs 1 h after injection. The kidneys and liver show high organ uptake. The organ distribution of 18F-FdUR in humans, obtained by a rectilinear PET scan (Figure 3 ), also shows a high level of activity in the bladder, liver and kidneys. Ishiwata et al . 28 have reported the rapid accumulation of FdUR in small intestine and spleen in rats and mice, which explains the high level of activity in these organs. Table 4 . At one hour FDOPA and FdUR show higher percentages of activity in the Blood Activity Clearance. Activity clearance data from blood for FDG, FDOPA and FdUR are shown in Figure  5 . The clearance of radioactivity from human blood, after administration of these com pounds, was shown by fitting the data to three exponential components. In every case the removal of 18F from the blood was rapid. The mean half-lives of the three components are listed in Table 5 .
Cumulated Activities in Source Organs.
The cumulated activities in source organs after the administration of FDG, FDOPA and FdUR are listed in Tables 6, 7 , and 8, respectively. Brain, heart and liver show high cumulated activities after the administration of FDG (Table 6 ). For FDOPA the results Table 4 . Percentage of Injected Activity Excreted in the Bladder after In travenous Administration of "T-labeled Radiopharmaceuticals.
* determined in two subjects . r determined in four subjects . decay corrected to injection time. were calculated with Equation 3 (except for brain, for which the cumulated activity was calculated with Equation 6) from the time-activity curves measured in humans (Figure 2 ). Bladder and kidneys are the organs showing the highest cumulated activity. For FdUR, the activities were obtained with Equation 7. After bladder content, the liver, kidneys and small intestine have high cumulated activity. Cumulated Activity in Bladder and the Rest of the Body. The calculated cumulated activities of these radiopharmaceuticals in the bladder contents appear in the respective tables for cumulated activity. They were determined, as was explained elsewhere, from the kidney-bladder model for FDOPA (Equation 9) , and from the data of Shani et al. 19) for FdUR. Cumulated FDG activity in the bladder contents was calculated from the experimental data with Equation 10. Cumulated activities calculated for the rest of the body also are listed at the bottoms of Tables 6, 7 
DISCUSSION
Because of the lack of information and difficulties in obtaining biokinetic data in humans, absorbed dose calculations had to be based in part on biodistribution data obtained from animal experiments. In addition, certain assumptions had to be made for radiation dosimetry purposes. For FdUR it was assumed that the organ distribution of 18F activity at 1 h in the dog represents the initial uptake by the organs in humans and that this distribution is present instantly after injection. The rapid blood clearance of 18F radioactivity in humans (Table 4 ) supports this assumption. It also was assumed that the efffective half-life is equal to the physical half-life of '8F, which gives a conservative estimate of the absorbed dose.
The organ distribution of FdUR in humans appears to be similar to the distribution of FdUR in dogs which was assumed for dosimetry purposes. Therefore, the absorbed dose estimated in humans may have acceptable accuracy. For FDOPA, studies in mice and dogs 16, 10) show similar results for the organ biodistribution of this radiopharmaceutical, but results obtained for humans show some differences, as described elsewhere. Tables 9 to 11 show that, excluding the bladder wall, the highest absorbed doses are received by the kidneys and pancreas when FDOPA is administered; kidneys and the small intestine for FdUR; and the heart, kidneys and brain on administration of FDG. The critical organ is the bladder wall, which received the highest dose when any of these compounds was administered. FDG, the most commonly used of these radiopharmaceuticals shows the lowest dose (1.2x10-' mGy/MBq). Our result for the FDG dose to the bladder wall agrees with the 1.1X10-1 mGy/MBq reported by Jones et al.9 , which also was estimated from human data. Harvey et al.10) reported an FDOPA dose of 6.89x10-' mGy/MBq to the bladder wall; whereas our result, calculated from the kidney-bladder model, gave 2.15X10-1 mGy/MBq. This difference is accounted for by the fact that they used the ICRP model for the GI tract and assumed a bladder content of 110 ml in their calculations, which is almost half the standard value (200 ml) recommended by the ICRP and MIRD Committee. Because of the latter assumption Harvey et al. overestimated the "S" value that corresponds to the bladder content as source and bladder wall as target , by approximately two fold the value calculated from the MIRD Tables, as the specific absorbed fraction used to calculate the S values is inversely proportional to the mass. Thus the absorbed dose to the bladder wall reported by Harvey et al. is overestimated by a factor of two. For this reason we think our result based on a bladder content of 200 ml is a more accurate estimation of the absorbed dose to the bladder wall. In the absorbed dose calculations we extrapolated, in some instances, data from animals to humans; therefore, it must be kept in mind that the estimated results may differ from those estimated from human data by a factor of 2-3 for the absorbed dose and by a factor of less than 2 for the effective dose equivalent, as pointed out by Roedler29). We have estimated the absorbed dose and effective dose equivalent to humans, in particular to the Japanese, that results from intravenous administrations of FDOPA, FdUR and FDG. These results can be used to estimate the limit of activity that can be administered to a patient and serve as a means of comparing the risk to benefit value of these nuclear medical procedures with those of other diagnostic procedures.
